November 30th 2023
Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.
November 12th 2023
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
View More
40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Gives Priority Review to Olaparib and Abiraterone for mCRPC Regardless of HRR Status
August 16th 2022Based on data showing that patients with metastatic castration-resistant prostate cancer may achieve benefit following treatment with olaparib plus abiraterone and prednisone or prednisolone regardless of homologous recombination repair mutational status, the FDA gave the combination priority review.